Multimodal action of MAS activation for systemic cancer cachexia therapy

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Cancer cachexia remains a largely intractable, deadly condition for patients with no approved, effective therapies. However, research progress over the past few decades demonstrates that cachexia is a disease with specific, targetable mechanisms. New work by Murphy and colleagues in this issue of Cancer Research suggests that activation of the alternative renin–angiotensin system with the nonpeptide Mas receptor agonist AVE 0991 holds promise for reducing muscle wasting in cancer. Their cell studies demonstrate on-target activity in skeletal muscle cells, whereas their mouse results suggest potentially more important systemic effects.

Original languageEnglish (US)
Pages (from-to)699-700
Number of pages2
JournalCancer Research
Volume79
Issue number4
DOIs
StatePublished - Feb 15 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Multimodal action of MAS activation for systemic cancer cachexia therapy'. Together they form a unique fingerprint.

  • Cite this